Brokerages Set Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Price Target at $6.57

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) has received an average recommendation of “Buy” from the seven brokerages that are currently covering the company, MarketBeat.com reports. Seven equities research analysts have rated the stock with a buy recommendation. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $6.57.

TSHA has been the topic of several recent analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $7.00 price target on shares of Taysha Gene Therapies in a report on Monday, April 28th. JMP Securities reaffirmed a “market outperform” rating and issued a $5.00 price target on shares of Taysha Gene Therapies in a report on Monday, April 28th. Canaccord Genuity Group increased their price objective on Taysha Gene Therapies from $8.00 to $9.00 and gave the company a “buy” rating in a research report on Friday, May 16th. Chardan Capital reiterated a “buy” rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a research report on Wednesday, February 26th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $6.00 price objective on shares of Taysha Gene Therapies in a research report on Thursday, April 10th.

Hedge Funds Weigh In On Taysha Gene Therapies

Institutional investors and hedge funds have recently bought and sold shares of the stock. Ground Swell Capital LLC bought a new position in Taysha Gene Therapies during the 4th quarter worth approximately $25,000. Cibc World Markets Corp bought a new position in Taysha Gene Therapies during the 4th quarter worth approximately $28,000. E Fund Management Co. Ltd. bought a new position in Taysha Gene Therapies during the 4th quarter worth approximately $31,000. Hsbc Holdings PLC grew its position in Taysha Gene Therapies by 65.6% during the 4th quarter. Hsbc Holdings PLC now owns 20,391 shares of the company’s stock worth $36,000 after acquiring an additional 8,076 shares during the last quarter. Finally, AXQ Capital LP bought a new position in Taysha Gene Therapies during the 4th quarter worth approximately $39,000. 77.70% of the stock is currently owned by institutional investors.

Taysha Gene Therapies Trading Down 5.1%

NASDAQ:TSHA opened at $2.61 on Friday. The company has a market cap of $560.27 million, a P/E ratio of 4.14 and a beta of 0.90. The stock’s fifty day moving average price is $1.87 and its two-hundred day moving average price is $1.89. Taysha Gene Therapies has a 1 year low of $1.05 and a 1 year high of $4.32. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.51 and a quick ratio of 5.51.

Taysha Gene Therapies (NASDAQ:TSHA) last posted its earnings results on Thursday, May 15th. The company reported ($0.08) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.08). The firm had revenue of $2.30 million for the quarter, compared to the consensus estimate of $1.48 million. Taysha Gene Therapies had a negative return on equity of 106.36% and a negative net margin of 229.67%. During the same quarter in the prior year, the business posted ($0.10) earnings per share. As a group, analysts expect that Taysha Gene Therapies will post -0.35 EPS for the current year.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.